Log in

Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination

6 Apr 2021 10:30 AM | Anonymous member (Administrator)

Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination

Date of preparation: 6 April, 2021

The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination. 

The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ.

https://www.tga.gov.au/media-release/specific-clotting-condition-reported-after-covid-19-vaccination

https://www.health.gov.au/news/atagi-statement-covid-19-vaccination-reported-case-of-thrombosis https://www.gov.nl.ca/covid-19/vaccine/astrazeneca-covishield-information/ https://covid19-sciencetable.ca/sciencebrief/vaccine-induced-prothrombotic-immune-thrombocytopenia-vipit-following-astrazeneca-covid-19-vaccination-interim-guidance-for-healthcare-professionals-in-emergency-department-and-inpatient-settings/

The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT.

For the full statement please go to the HSANZ Members only site


CONTACT

Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114


FOLLOW US

Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.

Powered by Wild Apricot Membership Software